All In Biotech

Drug Trial Radar · NCT05611801

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

AN OPEN-LABEL STUDY IN PEDIATRIC (<18 YEARS OF AGE), SEVERE HEMOPHILIA A PARTICIPANTS (COAGULATION FACTOR ACTIVITY <1%) WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY ≤2%) WITH OR WITHOUT INHIBITORS COMPARING 12 MONTHS OF HISTORICAL STANDARD TREATMENT TO MARSTACIMAB PROPHYLAXIS

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Dec 9, 2022

Primary completion

Sep 10, 2028

Study completion Sep 10, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 1 year, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called marstacimab) for the potential treatment of hemophilia in pediatric patients. This study will enroll pediatric participants from ages 1 to 17 years in a sequential manner. The study opened the enrollment to adolescent participants aged 12 to 17 years first. Then children aged 6 to 11 years erere permitted to enroll. Lastly, children aged 1 to 5 years are permitted to enroll. This study will enroll male participants who: * have severe Hemophilia A or moderately severe to severe Hemophilia B (with or without inhibitors) * have accurate historical records documenting all factor VIII, factor IX, or bypass agent infusions and hemophilia bleed events for at least 1 year prior to entering the study for participants from 6 to 17 years of age, and at least 3 months prior to entering the study for participants from 1 to 5 years of age * if a non-inhibitor patient, must be on a stable routine prophylaxis regimen with factor VIII or factor IX replacement products for at least 12 months prior to study entry for participants from 6 to 17 years of age, and least 3 months for participants aged from 1 to 5 years of age * if an inhibitor patient, must be on an on-demand bypass treatment regimen during the 12 months prior to study entry for participants from 6 to 17 years of age, and during the 3 months prior to study entry for participants aged from 1 to 5 years of age All participants in this study will receive marstacimab to use prophylactically. Marstacimab will be given once a week as a subcutaneous (under the skin) shot. The first dose of marstacimab will be given at the study site by the study site staff. During the 12-month treatment period, weekly doses of marstacimab can be given at home, or if preferred, the doses may be given by the study site staff. To help us determine if the study medicine is safe and effective, we will compare participant experiences when they are taking the study medicine to a historical period when they were not. Researchers want to see if the study medicine works to prevent the bleeding episodes commonly experienced by patients with Hemophilia. Participants will be in this study for about 14 months (approximately 1 month in a Screening period, 12 months receiving treatment, and 1 month in a follow-up period) during which they will visit the study site at least 10 times. If preferred, and if local regulations allow it, 2 of the study visits can be completed at the participant's home instead of at the study site. There will also be 6 scheduled telephone calls approximately every 2 months.

Conditions

  • Hemophilia A
  • Hemophilia B

Interventions

  • marstacimabDrug

    marstacimab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized bleeding rate (ABR) of treated bleeding eventsTime frame: Baseline (up to 12 months prior to informed consent) to the end of the 12-month treatment period
  2. Incidence of adverse events and serious adverse eventsTime frame: Screening through end of follow-up period (approximately 14 months)
  3. Incidence and severity of thrombotic eventsTime frame: Baseline to end of 12-month treatment period
  4. Incidence and severity of thrombotic microangiopathyTime frame: Baseline to end of 12-month treatment period
  5. Incidence and severity of disseminated intravascular coagulation/consumption coagulopathy eventsTime frame: Baseline to end of 12-month treatment period
  6. Immunogenicity (incidence of ADA and clinically significant persistent NAb against marstacimab)Time frame: Baseline to end of 12-month treatment period
  7. Incidence and severity of injection site reactionTime frame: Baseline to end of 12-month treatment period
  8. Incidence of severe hypersensitivity and anaphylactic reactionsTime frame: Baseline to end of 12-month treatment period

Locations

62 sites in 22 countries. Site status is shown where the registry gives one.

  • Intermountain - Primary Children's Hospital

    Salt Lake City, Utah · Recruiting

  • Arbesu Hematología

    Mendoza, Argentina · Recruiting

  • Murdoch Children's Research Institute

    Parkville, Australia · Recruiting

  • Medizinische Universität Wien

    Vienna, State of Vienna, Austria · Recruiting

  • Centro Estadual de Hemoterapia e Hematologia Marcos Daniel Santos - HEMOES

    Maruípe, Vitória, Brazil · Active not recruiting

  • Stollery Children's Hospital

    Edmonton, Alberta, Canada · Active not recruiting

  • Hamilton Health Sciences - McMaster University/McMaster Children's Hospital

    Hamilton, Ontario, Canada · Active not recruiting

  • Beijing Children's hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Southern Medical University Nanfang Hospital

    Guangzhou, Guangdong, China · Active not recruiting

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Active not recruiting

  • Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Tongji Hospital of Tongji Medical College of HUST/Pediatric Hematology Department Pharmacy

    Wuhan, Hubei, China · Recruiting

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, China · Active not recruiting

  • Institute of hematology&blood disease hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Fakultni nemocnice Brno

    Brno, Czechia · Recruiting

  • Fakultni nemocnice v Motole

    Prague, Czechia · Recruiting

  • Detska nemocnice FN Brno

    Brno, Brno-město, Czechia · Recruiting

  • Aarhus Universitetshospital, Skejby

    Aarhus N, Denmark · Recruiting

  • Aarhus University

    Aarhus N, Denmark · Recruiting

  • Rigshospitalet

    Copenhagen, Capital Region, Denmark · Recruiting

  • Charité Campus Virchow-Klinikum

    Berlin, Germany · Active not recruiting

  • Nirmal Hospital Pvt Ltd.

    Surat, Gujarat, India · Recruiting

  • K. J. Somaiya Hospital and Research Centre, Somaiya Ayurvihar Complex

    Mumbai, Maharashtra, India · Recruiting

  • Nil Ratan Sircar Medical College and Hospital

    Kolkata, West Bengal, India · Recruiting

  • Sheba Medical Center

    Ramat Gan, Central District, Israel · Recruiting

  • Azienda Ospedaliero Universitaria di Parma

    Parma, Italy · Recruiting

  • Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino

    Torino, Italy · Recruiting

  • IRCCS Istituto Giannina Gaslini

    Genoa, Liguria, Italy · Recruiting

  • Istituto Clinico Humanitas - Humanitas Mirasole SPA

    Rozzano, Milan, Italy · Recruiting

  • Ospedale Pediatrico Bambino Gesù IRCCS

    Rome, ROMA, Italy · Recruiting

  • Saga University Hospital

    Saga, Japan · Active not recruiting

  • Hyogo prefectural Kobe Children's Hospital

    Kobe, Hyōgo, Japan · Recruiting

  • Nagano Children's Hospital

    Azumino, Nagano, Japan · Active not recruiting

  • Nara Medical University Hospital

    Kashihara, Nara, Japan · Recruiting

  • Saitama Prefectural Children's Medical Center

    Saitama-shi, Saitama, Japan · Recruiting

  • King Fahad Specialist Hospital

    Dammam, Saudi Arabia · Active not recruiting

  • Detska fakultna nemocnica Kosice

    Košice, Slovakia · Recruiting

  • Univerzitna nemocnica Martin

    Martin, Slovakia · Recruiting

  • Worthwhile Clinical Trials

    Benoni, Gauteng, South Africa · Active not recruiting

  • Charlotte Maxeke Johannesburg Academic Hospital

    Johannesburg, Gauteng, South Africa · Active not recruiting

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.